INMB
INmune Bio Inc.
Price Chart
Latest Quote
$1.45
+0.09 (+7.04%)
Current Price
| Previous Close | $1.35 |
| Open | $1.37 |
| Day High | $1.50 |
| Day Low | $1.30 |
| Volume | 9,096,061 |
Stock Information
| Shares Outstanding | 26.59M |
| Total Debt | $1.51M |
| Cash Equivalents | $21.36M |
| Net Income | $-41.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $38.42M |
| EPS (TTM) | $-1.63 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $16.04M |
| Income | $-41.60M |
| Book/sh | $0.74 |
| Cash/sh | $0.80 |
| Employees | 21 |
Financial Ratios
| Quick Ratio | 4.11 |
| Current Ratio | 4.24 |
| Debt/Eq | 7.70 |
Returns & Margins
| ROA | -52.61% |
| ROE | -168.78% |
Ownership
| Insider Ownership | 11.16% |
| Institutional Ownership | 19.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.75 |
| P/B | 1.96 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $7.00 |
Technical Indicators
| SMA20 | $1.34 |
| SMA50 | $1.40 |
| SMA200 | $1.57 |
| RSI | 57.48 |
| ATR | 0.1038 |
| Shares Float | 22.16M |
| Short Float | 15.62% |
| Short Ratio | 7.92 |
| Volatility | 1.01 |
| Rel Volume | 12.06 |
Performance History
| Week | +11.15% |
| Month | +1.05% |
| Quarter | +18.44% |
| 6 Months | -23.14% |
| YTD | -6.17% |
| Year | -78.14% |
| 3 Years | -84.21% |
| 5 Years | -91.69% |
| 10 Years | -81.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.45 | 9,096,061 |
| 2026-06-24 | $1.35 | 273,100 |
| 2026-06-23 | $1.42 | 432,300 |
| 2026-06-22 | $1.43 | 284,400 |
| 2026-06-18 | $1.45 | 447,000 |
| 2026-06-17 | $1.30 | 252,900 |
| 2026-06-16 | $1.28 | 161,600 |
| 2026-06-15 | $1.28 | 219,400 |
| 2026-06-12 | $1.24 | 150,500 |
| 2026-06-11 | $1.27 | 235,500 |
| 2026-06-10 | $1.21 | 207,000 |
| 2026-06-09 | $1.22 | 262,700 |
| 2026-06-08 | $1.24 | 294,500 |
| 2026-06-05 | $1.26 | 327,700 |
| 2026-06-04 | $1.35 | 312,600 |
| 2026-06-03 | $1.32 | 391,900 |
| 2026-06-02 | $1.42 | 1,045,900 |
| 2026-06-01 | $1.39 | 181,600 |
| 2026-05-29 | $1.41 | 303,200 |
| 2026-05-28 | $1.42 | 208,800 |
| 2026-05-27 | $1.40 | 217,600 |
| 2026-05-26 | $1.43 | 238,700 |
About INmune Bio Inc.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
đ° Latest News
INmune Bio (INMB) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-06-01T21:15:43Z
INmune Bio (INMB) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-08T14:30:11Z
INmune Bio, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
INmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash Wisely
Simply Wall St. âĸ 2026-04-01T11:09:42Z
INmune Bio, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-31T12:30:00Z
INmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
GuruFocus.com âĸ 2026-03-31T03:01:07ZINmune Bio submits pre-submission package for CORDStrom with MHRA
TipRanks âĸ 2026-02-11T13:12:07Z
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks âĸ 2025-11-06T14:55:02Z
INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ...
GuruFocus.com âĸ 2025-10-31T03:03:34Z
INmune Bio (INMB) Loses 23.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks âĸ 2025-09-08T20:50:18Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $50,000 | $14,000 | $155,000 | $374,000 |
| Operating Revenue | $50,000 | $14,000 | $155,000 | $374,000 |
| Expenses | ||||
| Total Expenses | $30,919,000 | $42,649,000 | $29,896,000 | $26,325,000 |
| Other Income Expense | $-15,064,000 | $553,000 | $-267,000 | $-1,348,000 |
| Other Non Operating Income Expenses | $1,450,000 | $553,000 | $-267,000 | $-1,348,000 |
| Operating Expense | $30,919,000 | $42,649,000 | $29,896,000 | $26,325,000 |
| General And Administrative Expense | $10,260,000 | $9,483,000 | $9,623,000 | $9,258,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Normalized Income | $-29,419,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Net Income From Continuing And Discontinued Operation | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Total Operating Income As Reported | $-47,383,000 | $-42,635,000 | $-29,741,000 | $-25,951,000 |
| Net Income Common Stockholders | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Net Income | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Net Income Including Noncontrolling Interests | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Net Income Continuous Operations | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Pretax Income | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Special Income Charges | $-16,514,000 | $0 | - | - |
| Operating Income | $-30,869,000 | $-42,635,000 | $-29,741,000 | $-25,951,000 |
| Per Share | ||||
| Diluted EPS | $-1.86 | $-2.11 | $-1.67 | $-1.52 |
| Basic EPS | $-1.86 | $-2.11 | $-1.67 | $-1.52 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-14,271,000 | $-42,635,000 | $-29,741,000 | $-25,951,000 |
| Total Unusual Items | $-16,514,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-16,514,000 | $0 | - | - |
| Reconciled Depreciation | $84,000 | $0 | - | - |
| EBITDA (Bullshit earnings) | $-30,785,000 | $-42,635,000 | $-29,741,000 | $-25,951,000 |
| EBIT | $-30,869,000 | $-42,635,000 | $-29,741,000 | $-25,951,000 |
| Diluted Average Shares | $24,757,545 | $19,944,304 | $17,980,791 | $17,927,327 |
| Basic Average Shares | $24,757,545 | $19,944,304 | $17,980,791 | $17,927,327 |
| Diluted NI Availto Com Stockholders | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Impairment Of Capital Assets | $16,514,000 | $0 | - | - |
| Research And Development | $20,659,000 | $33,166,000 | $20,273,000 | $17,067,000 |
| Selling General And Administration | $10,260,000 | $9,483,000 | $9,623,000 | $9,258,000 |
| Other Gand A | $10,260,000 | $9,483,000 | $9,623,000 | $9,258,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $23,524,000 | $15,583,000 | $21,625,000 | $43,590,000 |
| Total Assets | $32,351,000 | $39,562,000 | $57,001,000 | $81,795,000 |
| Total Non Current Assets | $2,464,000 | $16,900,000 | $17,059,000 | $17,120,000 |
| Other Non Current Assets | $595,000 | $79,000 | $131,000 | $99,000 |
| Goodwill And Other Intangible Assets | $0 | $16,514,000 | $16,514,000 | $16,514,000 |
| Current Assets | $29,887,000 | $22,662,000 | $39,942,000 | $64,675,000 |
| Other Current Assets | $595,000 | $331,000 | $1,510,000 | $4,027,000 |
| Receivables | $4,541,000 | $1,409,000 | $2,442,000 | $8,461,000 |
| Taxes Receivable | $4,541,000 | $1,409,000 | $2,442,000 | $8,461,000 |
| Cash Cash Equivalents And Short Term Investments | $24,751,000 | $20,922,000 | $35,848,000 | $52,153,000 |
| Cash And Cash Equivalents | $24,751,000 | $20,922,000 | $35,848,000 | $52,153,000 |
| Other Intangible Assets | - | $16,514,000 | $16,514,000 | $16,514,000 |
| Prepaid Assets | - | $0 | $142,000 | $34,000 |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $1,034,000 | $384,000 | $10,437,000 | $15,310,000 |
| Long Term Debt And Capital Lease Obligation | $411,000 | $244,000 | $397,000 | $10,223,000 |
| Current Debt And Capital Lease Obligation | $623,000 | $140,000 | $10,040,000 | $5,087,000 |
| Current Debt | - | - | $9,921,000 | $5,000,000 |
| Other Current Borrowings | - | - | $9,921,000 | $5,000,000 |
| Long Term Debt | - | - | - | $9,697,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,827,000 | $7,465,000 | $18,862,000 | $21,691,000 |
| Total Non Current Liabilities Net Minority Interest | $411,000 | $244,000 | $397,000 | $10,773,000 |
| Current Liabilities | $8,416,000 | $7,221,000 | $18,465,000 | $10,918,000 |
| Current Deferred Liabilities | $0 | $517,000 | $489,000 | $616,000 |
| Payables And Accrued Expenses | $7,793,000 | $6,564,000 | $7,936,000 | $5,215,000 |
| Payables | $7,793,000 | $6,564,000 | $7,936,000 | $5,215,000 |
| Accounts Payable | $7,793,000 | $6,564,000 | $7,936,000 | $5,215,000 |
| Equity | ||||
| Common Stock Equity | $23,524,000 | $32,097,000 | $38,139,000 | $60,104,000 |
| Total Equity Gross Minority Interest | $23,524,000 | $32,097,000 | $38,139,000 | $60,104,000 |
| Stockholders Equity | $23,524,000 | $32,097,000 | $38,139,000 | $60,104,000 |
| Gains Losses Not Affecting Retained Earnings | $-737,000 | $-575,000 | $-799,000 | $-699,000 |
| Other Equity Adjustments | $-737,000 | $-575,000 | $-799,000 | $-699,000 |
| Retained Earnings | $-209,037,000 | $-163,104,000 | $-121,022,000 | $-91,014,000 |
| Other | ||||
| Ordinary Shares Number | $26,585,258 | $22,280,451 | $17,950,776 | $17,945,995 |
| Share Issued | $26,585,258 | $22,280,451 | $17,950,776 | $17,945,995 |
| Tangible Book Value | $23,524,000 | $15,583,000 | $21,625,000 | $43,590,000 |
| Invested Capital | $23,524,000 | $32,097,000 | $48,060,000 | $74,801,000 |
| Working Capital | $21,471,000 | $15,441,000 | $21,477,000 | $53,757,000 |
| Capital Lease Obligations | $1,034,000 | $384,000 | $516,000 | $613,000 |
| Total Capitalization | $23,524,000 | $32,097,000 | $38,139,000 | $69,801,000 |
| Additional Paid In Capital | $233,271,000 | $195,754,000 | $159,143,000 | $151,799,000 |
| Capital Stock | $27,000 | $22,000 | $817,000 | $18,000 |
| Common Stock | $27,000 | $22,000 | $817,000 | $18,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $411,000 | $244,000 | $397,000 | $526,000 |
| Current Capital Lease Obligation | $623,000 | $140,000 | $119,000 | $87,000 |
| Net PPE | $1,869,000 | $307,000 | $414,000 | $507,000 |
| Gross PPE | $1,869,000 | $307,000 | $414,000 | $507,000 |
| Other Properties | $955,000 | - | - | - |
| Buildings And Improvements | $914,000 | $307,000 | $414,000 | $507,000 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Accrued Expenses | - | - | $0 | $550,000 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,624,000 | $-33,361,000 | $-11,980,000 | $-22,686,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-22,582,000 | $-33,361,000 | $-11,980,000 | $-22,686,000 |
| Cash Flow From Continuing Operating Activities | $-22,582,000 | $-33,361,000 | $-11,980,000 | $-22,686,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,042,000 | - | - | - |
| Investing Cash Flow | $-1,042,000 | $0 | - | $0 |
| Cash Flow From Continuing Investing Activities | $-1,042,000 | $0 | - | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $27,544,000 | $27,789,000 | $775,000 | $699,000 |
| Financing Cash Flow | $27,612,000 | $18,211,000 | $-4,225,000 | $729,000 |
| Cash Flow From Continuing Financing Activities | $27,612,000 | $18,211,000 | $-4,225,000 | $729,000 |
| Net Common Stock Issuance | $27,544,000 | $27,789,000 | $775,000 | $699,000 |
| Common Stock Issuance | $27,544,000 | $27,789,000 | $775,000 | $699,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-10,000,000 | $-5,000,000 | $0 |
| Interest Paid Supplemental Data | $0 | $1,690,000 | $1,778,000 | $1,372,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $24,751,000 | $20,922,000 | $35,848,000 | $52,153,000 |
| Beginning Cash Position | $20,922,000 | $35,848,000 | $52,153,000 | $74,810,000 |
| Effect Of Exchange Rate Changes | $-159,000 | $224,000 | $-100,000 | $-700,000 |
| Changes In Cash | $3,988,000 | $-15,150,000 | $-16,205,000 | $-21,957,000 |
| Proceeds From Stock Option Exercised | $68,000 | $422,000 | $0 | $30,000 |
| Net Issuance Payments Of Debt | $0 | $-10,000,000 | $-5,000,000 | $0 |
| Net Long Term Debt Issuance | $0 | $-10,000,000 | $-5,000,000 | $0 |
| Long Term Debt Payments | $0 | $-10,000,000 | $-5,000,000 | $0 |
| Net PPE Purchase And Sale | $-1,042,000 | $0 | - | - |
| Purchase Of PPE | $-1,042,000 | $0 | - | - |
| Change In Working Capital | $-2,531,000 | $1,037,000 | $10,436,000 | $-2,864,000 |
| Change In Other Working Capital | $-517,000 | $28,000 | $-127,000 | $142,000 |
| Change In Other Current Liabilities | $43,000 | $-25,000 | $-4,000 | $-33,000 |
| Change In Other Current Assets | $-516,000 | $52,000 | $-32,000 | $0 |
| Change In Payables And Accrued Expense | $1,855,000 | $-1,372,000 | $2,171,000 | $1,753,000 |
| Change In Payable | $1,855,000 | $-1,372,000 | $2,721,000 | $1,402,000 |
| Change In Account Payable | $1,855,000 | $-1,372,000 | $2,721,000 | $1,402,000 |
| Change In Prepaid Assets | $-264,000 | $1,321,000 | $2,409,000 | $-1,769,000 |
| Change In Receivables | $-3,132,000 | $1,033,000 | $6,019,000 | $-2,957,000 |
| Other Non Cash Items | $-626,000 | $79,000 | $224,000 | $239,000 |
| Stock Based Compensation | $9,910,000 | $7,605,000 | $7,368,000 | $7,149,000 |
| Asset Impairment Charge | $16,514,000 | $0 | $0 | $89,000 |
| Depreciation Amortization Depletion | $84,000 | $0 | - | - |
| Depreciation And Amortization | $84,000 | $0 | - | - |
| Depreciation | $84,000 | $0 | - | - |
| Net Income From Continuing Operations | $-45,933,000 | $-42,082,000 | $-30,008,000 | $-27,299,000 |
| Change In Accrued Expense | - | $0 | $-550,000 | $351,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Common Stock Payments | - | - | - | - |
Fetched: 2026-06-25